Cargando…

Targeted treatments for cervical cancer: a review

Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%–95% of women with early stage cancer, the recurrent and metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Peralta-Zaragoza, Oscar, Bermúdez-Morales, Víctor Hugo, Pérez-Plasencia, Carlos, Salazar-León, Jonathan, Gómez-Cerón, Claudia, Madrid-Marina, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493318/
https://www.ncbi.nlm.nih.gov/pubmed/23144564
http://dx.doi.org/10.2147/OTT.S25123
_version_ 1782249241637289984
author Peralta-Zaragoza, Oscar
Bermúdez-Morales, Víctor Hugo
Pérez-Plasencia, Carlos
Salazar-León, Jonathan
Gómez-Cerón, Claudia
Madrid-Marina, Vicente
author_facet Peralta-Zaragoza, Oscar
Bermúdez-Morales, Víctor Hugo
Pérez-Plasencia, Carlos
Salazar-León, Jonathan
Gómez-Cerón, Claudia
Madrid-Marina, Vicente
author_sort Peralta-Zaragoza, Oscar
collection PubMed
description Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%–95% of women with early stage cancer, the recurrent and metastatic disease remains a major cause of cancer death. Many efforts have been made to design new drugs and develop gene therapies to treat cervical cancer. In recent decades, research on treatment strategies has proposed several options, including the role of HPV E6 and E7 oncogenes, which are retained and expressed in most cervical cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype. Other efforts have been focused on antitumor immunotherapy strategies. It is known that during the development of cervical cancer, a cascade of abnormal events is induced, including disruption of cellular cycle control, perturbation of antitumor immune response, alteration of gene expression, and deregulation of microRNA expression. Thus, in this review article we discuss potential targets for the treatment of cervical cancer associated with HPV infection, with special attention to immunotherapy approaches, clinical trials, siRNA molecules, and their implications as gene therapy strategies against cervical cancer development.
format Online
Article
Text
id pubmed-3493318
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34933182012-11-09 Targeted treatments for cervical cancer: a review Peralta-Zaragoza, Oscar Bermúdez-Morales, Víctor Hugo Pérez-Plasencia, Carlos Salazar-León, Jonathan Gómez-Cerón, Claudia Madrid-Marina, Vicente Onco Targets Ther Review Cervical cancer is the second most common cause of cancer death in women worldwide and the development of new diagnosis, prognostic, and treatment strategies merits special attention. Although surgery and chemoradiotherapy can cure 80%–95% of women with early stage cancer, the recurrent and metastatic disease remains a major cause of cancer death. Many efforts have been made to design new drugs and develop gene therapies to treat cervical cancer. In recent decades, research on treatment strategies has proposed several options, including the role of HPV E6 and E7 oncogenes, which are retained and expressed in most cervical cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype. Other efforts have been focused on antitumor immunotherapy strategies. It is known that during the development of cervical cancer, a cascade of abnormal events is induced, including disruption of cellular cycle control, perturbation of antitumor immune response, alteration of gene expression, and deregulation of microRNA expression. Thus, in this review article we discuss potential targets for the treatment of cervical cancer associated with HPV infection, with special attention to immunotherapy approaches, clinical trials, siRNA molecules, and their implications as gene therapy strategies against cervical cancer development. Dove Medical Press 2012-11-02 /pmc/articles/PMC3493318/ /pubmed/23144564 http://dx.doi.org/10.2147/OTT.S25123 Text en © 2012 Peralta-Zaragoza et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Peralta-Zaragoza, Oscar
Bermúdez-Morales, Víctor Hugo
Pérez-Plasencia, Carlos
Salazar-León, Jonathan
Gómez-Cerón, Claudia
Madrid-Marina, Vicente
Targeted treatments for cervical cancer: a review
title Targeted treatments for cervical cancer: a review
title_full Targeted treatments for cervical cancer: a review
title_fullStr Targeted treatments for cervical cancer: a review
title_full_unstemmed Targeted treatments for cervical cancer: a review
title_short Targeted treatments for cervical cancer: a review
title_sort targeted treatments for cervical cancer: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493318/
https://www.ncbi.nlm.nih.gov/pubmed/23144564
http://dx.doi.org/10.2147/OTT.S25123
work_keys_str_mv AT peraltazaragozaoscar targetedtreatmentsforcervicalcancerareview
AT bermudezmoralesvictorhugo targetedtreatmentsforcervicalcancerareview
AT perezplasenciacarlos targetedtreatmentsforcervicalcancerareview
AT salazarleonjonathan targetedtreatmentsforcervicalcancerareview
AT gomezceronclaudia targetedtreatmentsforcervicalcancerareview
AT madridmarinavicente targetedtreatmentsforcervicalcancerareview